Articles
The leading cause of cancer death among men and women is lung cancer. According to the American Cancer Society (ACS), more people die of lung cancer than of breast, colon, and prostate cancers combined. Because this deadly disease affects so many Americans, lets delve into these lung cancer–related statistics.
Lung cancer (both small cell and non–small cell) is the second most common cancer in both men (after prostate cancer) and women (after breast cancer).
Approximately 14% of all new cancers are lung cancers.
Read More ›The link between cancer and thrombosis has been known for many years. Recently this connection has come to the forefront with increased recognition by healthcare providers and mandates by governing bodies. The results of a thromboembolic event can be catastrophic in a patient with cancer. Read More ›
With advances in the diagnosis and treatment of cancer, the estimated 5-year survival rate for cancer patients has significantly improved to approximately 67%.1 The most common malignancies in men and women in the United States—breast and prostate cancers—have 2 of the highest 5-year survival rates reported, at 90% and 99%, respectively.1 As oncology patients are living longer, bone health has become a pertinent issue in the treatment of both metastatic and nonmetastatic oncology patients.2
Read More ›Flexible sigmoidoscopy, which has fewer side effects, requires less bowel preparation, and presents a lower risk of bowel perforation than colonoscopy, is effective in decreasing the rates of new colorectal cancer cases and deaths, according to results from a study that spanned almost 20 years. The study is published online in the New England Journal of Medicine.
Read More ›For privately insured Americans in 2010, rising care prices were the primary driver of healthcare costs, according to the first report from the Health Care Cost Institute (HCCI).
Read More ›The FDA-approved drug daclizumab improves the survival of breast cancer patients taking a cancer vaccine by 30% compared with those patients not taking daclizumab, according to a recent study published in Science Translational Medicine.
A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania proposed that daclizumab would be effective in diminishing regulatory T cells (Tregs) and rebuilding the immune system’s ability to fight tumors.
Read More ›A hormone-depleting drug can help eliminate or nearly eliminate aggressive, nonmetastatic prostate cancer tumors, according to a clinical study.
Read More ›For women who have ductal carcinoma in situ (DCIS) of the breast, breast brachytherapy with a strut-based applicator appears to be an effective treatment, according to a groundbreaking multisite study. This form of accelerated partial breast irradiation (APBI) is a 5-day therapy that follows lumpectomy surgery.
Read More ›In a study of more than 20,000 patients 65 and older with non–small cell lung cancer (NSCLC), treatment rates declined more in relation with increasing age than with the worsening of other illnesses.
The study, led by a team at the San Francisco VA Medical Center (SFVAMC) and University of California San Francisco (UCSF), found that for all stages of cancer, younger patients were more apt to receive treatment than older patients, regardless of general health and prognosis.
Read More ›